SEQUENCE LISTING

<110> Children's Medical Center Corporation
       Ashkar, Samy

<120> Osteopontin-Coated Surfaces and Methods of Use

<130> CMCC 779

<150> US 60/241,248
<151> 2000-10-18

<150> US 60/327,273
<151> 2001-10-05

<160> 16

<170> PatentIn version 3.1

<210> 1
<211> 314
<212> PRT
<213> Homo sapiens

<400> 1

Met Arg Ile Ala Val Ile Cys Phe Cys Leu Leu Gly Ile Thr Cys Ala
1   5   10   15

Ile Pro Val Lys Gln Ala Asp Ser Gly Ser Ser Glu Glu Lys Gln Leu
            20   25   30

Tyr Asn Lys Tyr Pro Asp Ala Val Ala Thr Trp Leu Asn Pro Asp Pro
        35   40   45

Ser Gln Lys Gln Asn Leu Leu Ala Pro Gln Asn Ala Val Ser Ser Glu
    50   55   60

Glu Thr Asn Asp Phe Lys Gln Glu Thr Leu Pro Ser Lys Ser Asn Glu
65   70   75   80

Ser His Asp His Met Asp Asp Met Asp Asp Glu Asp Asp Asp His
                85   90   95

Val Asp Ser Gln Asp Ser Ile Asp Ser Asn Asp Ser Asp Asp Val Asp
                100   105   110

Asp Thr Asp Asp Ser His Gln Ser Asp Glu Ser His His Ser Asp Glu
        115   120   125

Ser Asp Glu Leu Val Thr Asp Phe Pro Thr Asp Leu Pro Ala Thr Glu
    130   135   140

Val Phe Thr Pro Val Val Pro Thr Val Asp Thr Tyr Asp Gly Arg Gly
145   150   155   160

Asp Ser Val Val Tyr Gly Leu Arg Ser Lys Ser Lys Lys Phe Arg Arg
            165   170   175

Pro Asp Ile Gln Tyr Pro Asp Ala Thr Asp Glu Asp Ile Thr Ser His
        180   185   190

Met Glu Ser Glu Glu Leu Asn Gly Ala Tyr Lys Ala Ile Pro Val Ala
        195   200   205

Gln Asp Leu Asn Ala Pro Ser Asp Trp Asp Ser Arg Gly Lys Asp Ser
    210   215   220

Tyr Glu Thr Ser Gln Leu Asp Asp Gln Ser Ala Glu Thr His Ser His
225   230   235   240

Lys Gln Ser Arg Leu Tyr Lys Arg Lys Ala Asn Asp Glu Ser Asn Glu
            245   250   255

His Ser Asp Val Ile Asp Ser Gln Glu Leu Ser Lys Val Ser Arg Glu
        260   265   270

Phe His Ser His Glu Phe His Ser His Glu Asp Met Leu Val Val Asp
        275   280   285

```
Pro Lys Ser Lys Glu Glu Asp Lys His Leu Lys Phe Arg Ile Ser His
    290                   295                   300


Glu Leu Asp Ser Ala Ser Ser Glu Val Asn
305                   310



<210>  2
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Osteopontin-derived peptide

<400>  2

Leu Val Leu Asp Pro Lys
1               5



<210>  3
<211>  6
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Osteopontin fragment

<400>  3

Leu Val Val Asp Pro Lys
1               5



<210>  4
<211>  5
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Artificial peptide sequence

<400>  4
```

Arg Gly Arg Asp Ser
1   5

<210> 5
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificial peptide sequence

<400> 5

Gly Arg Gly Asp Ser
1   5

<210> 6
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificial peptide sequence

<400> 6

Val Phe Thr Pro Val Val Pro Thr Val Asp Thr Tyr Asp Gly Arg Gly
1   5   10   15

Asp Ser Val Val Tyr Gly Leu Arg Ser Lys Ser Lys Lys Phe Arg Arg
            20   25   30

<210> 7
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificial peptide sequence

<400> 7

Val Phe Thr Pro Val Val Pro Thr Val Asp Thr Tyr Asp Gly Arg Gly
1   5   10   15

Asp Ser Val Val Tyr Gly Leu Arg Ser Lys Ser Lys Lys Phe Arg Arg
       20   25   30

Pro

<210> 8
<211> 40
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificial peptide sequence

<400> 8

Arg Ser Arg Arg Ala Thr Glu Val Phe Thr Pro Val Val Pro Thr Val
1   5   10   15

Asp Thr Tyr Asp Gly Arg Gly Asp Ser Val Val Tyr Gly Leu Arg Ser
       20   25   30

Lys Ser Lys Lys Phe Arg Arg Pro
       35   40

<210> 9
<211> 49
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificial peptide sequence

<400> 9

Ser Asp Glu Leu Val Thr Asp Phe Pro Thr Asp Leu Pro Ala Thr Glu
1   5   10   15

Val Phe Thr Pro Val Val Pro Thr Val Asp Thr Tyr Asp Gly Arg Gly
       20   25   30

```
Asp Ser Val Val Tyr Gly Leu Arg Ser Lys Ser Lys Lys Phe Arg Arg
        35                  40              45

Pro
```

<210> 10
<211> 40
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificial peptide sequence

<400> 10

```
Arg Ser Arg Arg Ala Thr Glu Val Phe Thr Pro Val Val Pro Thr Val
1                5                10                  15

Asp Thr Tyr Asp Gly Arg Gly Asp Ser Val Val Tyr Gly Arg Arg Ser
            20                  25                  30

Lys Ser Lys Lys Phe Arg Arg Pro
        35                  40
```

<210> 11
<211> 63
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificial peptide sequence

<400> 11

```
Arg Ser Arg Arg Ala Thr Glu Val Phe Thr Pro Val Val Pro Thr Val
1                5                10                  15

Asp Thr Tyr Asp Gly Arg Gly Asp Ser Val Val Tyr Gly Arg Arg Ser
            20                  25                  30
```

Lys Ser Lys Lys Phe Arg Arg Pro Ala Gly Ala Ala Gly Gly Pro Ala
        35   40   45

Gly Pro Ala Gly Pro Ala Gly Pro Ala Gly Pro Ala Gly Pro Ala
      50   55   60

<210> 12
<211> 36
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificial peptide sequence

<400> 12

Arg Ser Arg Arg Val Phe Thr Pro Phe Ile Pro Thr Glu Ser Ala Asn
1   5   10   15

Asp Gly Arg Gly Asp Ser Val Ala Tyr Gly Leu Lys Ser Lys Ser Lys
            20   25   30

Lys Phe Arg Arg
            35

<210> 13
<211> 32
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificial peptide sequence

<400> 13

Asp Thr Phe Thr Pro Ile Val Pro Thr Val Asp Val Pro Asn Gly Arg
1   5   10   15

Phe Asp Ser Leu Ala Tyr Gly Leu Lys Ser Lys Ser Lys Lys Phe Gln
            20   25   30

<210> 14
<211> 40
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificial peptide sequence

<400> 14

Arg Ser Arg Arg Ala Thr Glu Val Phe Thr Pro Val Val Pro Thr Val
1   5   10   15

Asp Thr Tyr Asp Gly Arg Ala Asp Ser Val Val Tyr Gly Arg Arg Ser
            20   25   30

Lys Ser Lys Lys Phe Arg Arg Pro
        35   40

<210> 15
<211> 40
<212> PRT
<213> Artificial Sequence

<220>
<223> Artificial peptide sequence

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> Acetyl-modified N-terminus

<400> 15

Arg Ser Arg Arg Ala Thr Glu Val Phe Thr Pro Val Val Pro Thr Val
1   5   10   15

Asp Thr Tyr Asp Gly Arg Gly Asp Ser Val Val Tyr Gly Leu Arg Ser
            20   25   30

```
Lys Ser Lys Lys Phe Arg Arg Pro
         35                  40
```

```
<210>  16
<211>  59
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Osteopontin fragment

<400>  16
```

```
Glu His Ser Asp Val Ile Asp Ser Gln Glu Leu Ser Lys Val Ser Arg
1                   5                   10                  15


Glu Phe His Ser His Glu Phe His Ser His Glu Asp Met Leu Val Val
              20                  25                  30


Asp Pro Lys Ser Lys Glu Glu Asp Lys His Leu Lys Phe Arg Ile Ser
              35                  40                  45


His Glu Leu Asp Ser Ala Ser Ser Glu Val Asn
      50                  55
```